ALX Oncology Limited (NASDAQ:INZY) Major Shareholder Purchases $10,000,000.00 in Stock

ALX Oncology Limited (NASDAQ:INZY) major shareholder Longitude Capital Partners Iii bought 625,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was acquired at an average price of $16.00 per share, with a total value of $10,000,000.00. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of INZY stock opened at $19.88 on Friday. ALX Oncology Limited has a fifty-two week low of $16.10 and a fifty-two week high of $22.19.

About ALX Oncology

Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis.

Featured Article: Why Dividend Stocks May Be Right for You

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with's FREE daily email newsletter.